Literature DB >> 21182455

Cell-specific aptamer-mediated targeted drug delivery.

Jiehua Zhou1, John J Rossi.   

Abstract

Nucleic acid aptamers are in vitro-selected small, single-stranded DNA or RNA oligonucleotides that can specifically recognize their target on the basis of their unique 3-dimensional structures. Recent advances in the development of escort aptamers to deliver and enhance the efficacy of other therapeutic agents have drawn enthusiasm in exploiting cell-type-specific aptamers as drug delivery vehicles. This review mainly focuses on the recent developments of aptamer-mediated targeted delivery systems. We also place particular emphasis on aptamers evolved against cell membrane receptors and possibilities for translation to clinical applications.

Mesh：

Substances：

Year:  2010        PMID： 21182455      PMCID： PMC3043981          DOI： 10.1089/oli.2010.0264

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN： 1545-4576


  76 in total

1.  Escort aptamers: a delivery service for diagnosis and therapy.

Authors:  B J Hicke; A W Stephens
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

Review 2.  In vitro selection of nucleic acids for diagnostic applications.

Authors:  J Hesselberth; M P Robertson; S Jhaveri; A D Ellington
Journal:  J Biotechnol       Date:  2000-03       Impact factor: 3.307

3.  Targeting the variable surface of African trypanosomes with variant surface glycoprotein-specific, serum-stable RNA aptamers.

Authors:  Mihaela Lorger; Markus Engstler; Matthias Homann; H Ulrich Göringer
Journal:  Eukaryot Cell       Date:  2003-02

4.  Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen.

Authors:  M Blank; T Weinschenk; M Priemer; H Schluesener
Journal:  J Biol Chem       Date:  2001-02-13       Impact factor: 5.157

5.  Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120.

Authors:  N Sayer; J Ibrahim; K Turner; A Tahiri-Alaoui; W James
Journal:  Biochem Biophys Res Commun       Date:  2002-05-10       Impact factor: 3.575

Review 6.  A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy?

Authors:  J Tasch; M Gong; M Sadelain; W D Heston
Journal:  Crit Rev Immunol       Date:  2001       Impact factor: 2.214

7.  Tenascin-C aptamers are generated using tumor cells and purified protein.

Authors:  B J Hicke; C Marion; Y F Chang; T Gould; C K Lynott; D Parma; P G Schmidt; S Warren
Journal:  J Biol Chem       Date:  2001-10-04       Impact factor: 5.157

8.  Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state.

Authors:  Y Altschuler; C L Kinlough; P A Poland; J B Bruns; G Apodaca; O A Weisz; R P Hughey
Journal:  Mol Biol Cell       Date:  2000-03       Impact factor: 4.138

9.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

Authors:  Shawn E Lupold; Brian J Hicke; Yun Lin; Donald S Coffey
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

Review 10.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698
View more
  53 in total

1.  Lipophilic Conjugates for Carrier-Free Delivery of RNA Importable into Human Mitochondria.

Authors:  Ilya Dovydenko; Mariya Meschaninova; Anne-Marie Heckel; Ivan Tarassov; Alya Venyaminova; Nina Entelis
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Optimizing siRNA delivery to the genital mucosa.

Authors:  Joseph A Katakowski; Deborah Palliser
Journal:  Discov Med       Date:  2011-02       Impact factor: 2.970

3.  An in Vitro Selection Strategy Identifying Naked DNA That Localizes to Cell Nuclei.

Authors:  John Smestad; Brandon Wilbanks; Louis J Maher
Journal:  J Am Chem Soc       Date:  2019-11-12       Impact factor: 15.419

4.  Identification of an aptamer binding to human osteogenic-induced progenitor cells.

Authors:  Nina Ardjomandi; Jan Niederlaender; Wilhelm K Aicher; Siegmar Reinert; Ernst Schweizer; Hans-Peter Wendel; Dorothea Alexander
Journal:  Nucleic Acid Ther       Date:  2013-01-04       Impact factor: 5.486

5.  UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C.

Authors:  Hazel T Mufhandu; Elin S Gray; Maphuti C Madiga; Nancy Tumba; Kabamba B Alexandre; Thandeka Khoza; Constantinos Kurt Wibmer; Penny L Moore; Lynn Morris; Makobetsa Khati
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 6.  Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.

Authors:  Jiehua Zhou; John Rossi
Journal:  J Investig Med       Date:  2014-10       Impact factor: 2.895

7.  Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells.

Authors:  William H Thiel; Kristina W Thiel; Katie S Flenker; Tom Bair; Adam J Dupuy; James O McNamara; Francis J Miller; Paloma H Giangrande
Journal:  Methods Mol Biol       Date:  2015

8.  Self-Assembled Aptamer-Nanomedicine for Targeted Chemotherapy and Gene Therapy.

Authors:  Nianxi Zhao; Zihua Zeng; Youli Zu
Journal:  Small       Date:  2017-12-04       Impact factor: 13.281

9.  Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.

Authors:  Partha Ray; Marcus A Cheek; Mariam L Sharaf; Na Li; Andrew D Ellington; Bruce A Sullenger; Barbara Ramsay Shaw; Rebekah R White
Journal:  Nucleic Acid Ther       Date:  2012-10       Impact factor: 5.486

Review 10.  Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.

Authors:  Jiehua Zhou; John J Rossi
Journal:  BioDrugs       Date:  2012-12-01       Impact factor: 5.807
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.